AbbVie To Acquire Landos Biopharma At $20.42/share In Cash
(RTTNews) - AbbVie Inc. (ABBV) and Landos Biopharma, Inc. (LABP) announced Monday a definitive agreement under which AbbVie will acquire biopharmaceutical company Landos.
Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
NLRX1 regulates immunometabolism and inflammation, and its activation impacts multiple mechanisms of inflammatory bowel disease (IBD) pathogenesis. The randomized controlled Phase 2 NEXUS clinical trial evaluating NX-13 in UC is currently enrolling patients in the United States and Europe (NCT05785715).
Under the terms of the agreement, AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone.
The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos' stockholders.
AbbVie Boosts FY24 Outlook - Update
AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis
AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients
AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO
AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln
AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin
AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint
